etrasimod

money trend loss dollar stock down
Biotech

Ventyx misses with investors amid comparisons to BMS, Pfizer

The phase 2 hit its primary endpoint, but doubts about whether the candidate has an edge over rival S1P1 modulators sent Ventyx’s stock down.
Nick Paul Taylor Oct 10, 2023 6:30am
rocketship new blast off start up business development break off acquisition split

Pfizer partners with Roivant for new inflammatory-focused Vant

Dec 1, 2022 10:30am